ストックスクリーナーアプリを入手
0.5799
1.40%
0.008
アフターアワーズ：
.57
-0.0099
-1.71%
前日終値:
$0.5719
開ける：
$0.574
24時間の取引高:
1.93M
Relative Volume:
0.11
時価総額：
$79.70M
収益：
-
当期純損益:
$-12.89M
株価収益率:
-0.2292
EPS:
-2.53
ネットキャッシュフロー:
$-11.95M
1週間 パフォーマンス:
+2.01%
1か月 パフォーマンス:
-3.08%
6か月 パフォーマンス:
+58.18%
1年 パフォーマンス:
-46.31%
1日の値動き範囲:
$0.556
$0.5799
1週間の範囲:
$0.5376
$0.60
52週間の値動き範囲:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
PSTV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.5799 | 78.60M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | アップグレード | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Plus Therapeutics Inc (PSTV) 最新ニュース
How Plus Therapeutics Inc. stock reacts to job market dataRetail Investor Activity & Master Technical Analysis With Free Tools - bollywoodhelpline.com
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru
Death Cross: How Plus Therapeutics Inc. stock reacts to job market data2025 Price Targets & Low Volatility Stock Recommendations - ulpravda.ru
Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда
Inflation Data: Can Plus Therapeutics Inc. stock continue upward trendTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Can Plus Therapeutics Inc. stock continue upward trendJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - Улправда
Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда
Plus Therapeutics, Inc. (PSTV) Presents at 2025 San Antonio Breast Cancer Symposium (SABCS)Slideshow - Seeking Alpha
Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital - MarketBeat
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Analyst Jason Kolbert Maintains 'Buy' Rating for Plus Therapeuti - GuruFocus
CNSide Diagnostics expands lab licenses to three more states - Investing.com
Plus Therapeutics Expands CNSide Assay Platform to State of California - The Manila Times
Plus Therapeutics (Nasdaq: PSTV) CNSide test now licensed in 48 states, reaching over 90% of U.S. - Stock Titan
Plus Therapeutics adds key personnel to CNSide Diagnostics team By Investing.com - Investing.com Canada
Plus Therapeutics (PSTV) Expands CNSide Diagnostics Team with Ke - GuruFocus
Plus Therapeutics adds key personnel to CNSide Diagnostics team - Investing.com
Plus Therapeutics Announces Key Hires to Strengthen Operations at CNSide Diagnostics, LLC - Quiver Quantitative
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - The Manila Times
Why global investors buy Plus Therapeutics Inc. (XMP0) stockWeekly Investment Recap & Reliable Breakout Forecasts - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Reports Positive Phase 1 Data for REYOBIQ in Leptomeningeal Metastases and Glioblastoma at WFNOS/SNO Annual Meeting | PSTV Stock News - Quiver Quantitative
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser
Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ
Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser
How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
Plus Therapeutics granted 180-day to regain compliance with Nasdaq - MSN
Why Plus Therapeutics Inc. stock is favored by top institutions - Newser
Plus Therapeutics (PSTV) Analyst Rating Update: Maintain Buy Rat - GuruFocus
Plus Therapeutics to present breast cancer treatment data at SABCS By Investing.com - Investing.com Nigeria
Plus Therapeutics to present breast cancer treatment data at SABCS - Investing.com
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Plus Therapeutics, Inc. Announces Abstract Acceptance for Spotlight Presentation at San Antonio Breast Cancer Symposium 2025 on Rhenium (186Re) obisbemeda for Leptomeningeal Metastases Treatment - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) lands SABCS 2025 spotlight for LM Phase 1 trial - Stock Titan
HC Wainwright Expects Weaker Earnings for Plus Therapeutics - MarketBeat
Plus Therapeutics Eyes Expansion Despite Wider Quarterly Loss - Finimize
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 - Investing.com Nigeria
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 By Investing.com - Investing.com South Africa
Plus Therapeutics Inc (PSTV) 財務データ
収益
当期純利益
現金流量
EPS
0.08%
0.21%
大文字化:
|
ボリューム (24 時間):